Siemann DW - Search Results

1

Effect of bevacizumab on angiogenesis and growth of canine osteosarcoma cells xenografted in athymic mice.

Scharf VF, Farese JP, Coomer AR, Milner RJ, Taylor DP, Salute ME, Chang MN, Neal D, Siemann DW. Scharf VF, et al. Among authors: siemann dw. Am J Vet Res. 2013 May;74(5):771-8. doi: 10.2460/ajvr.74.5.771. Am J Vet Res. 2013. PMID: 23627391 Free article.

2

Intrinsic radiosensitivity and repair of sublethal radiation-induced damage in canine osteosarcoma cell lines.

Fitzpatrick CL, Farese JP, Milner RJ, Salute ME, Rajon DA, Morris CG, Bova FJ, Lurie DM, Siemann DW. Fitzpatrick CL, et al. Among authors: siemann dw. Am J Vet Res. 2008 Sep;69(9):1197-202. doi: 10.2460/ajvr.69.9.1197. Am J Vet Res. 2008. PMID: 18764694 Free article.

3

Development of an intramuscular xenograft model of canine osteosarcoma in mice for evaluation of the effects of radiation therapy.

Coomer AR, Farese JP, Milner R, Taylor D, Salute ME, Rajon DA, Bova FJ, Siemann DW. Coomer AR, et al. Among authors: siemann dw. Am J Vet Res. 2009 Jan;70(1):127-33. doi: 10.2460/ajvr.70.1.127. Am J Vet Res. 2009. PMID: 19119958 Free article.

4

Effects of aurothiomalate treatment on canine osteosarcoma in a murine xenograft model.

Scharf VF, Farese JP, Siemann DW, Abbott JR, Kiupel M, Salute ME, Milner RJ. Scharf VF, et al. Among authors: siemann dw. Anticancer Drugs. 2014 Mar;25(3):332-9. doi: 10.1097/CAD.0000000000000061. Anticancer Drugs. 2014. PMID: 24304691

5

Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor.

Shi W, Siemann DW. Shi W, et al. Among authors: siemann dw. Br J Cancer. 2002 Jul 1;87(1):119-26. doi: 10.1038/sj.bjc.6600416. Br J Cancer. 2002. PMID: 12085267 Free PMC article.

6

Differentiation and definition of vascular-targeted therapies.

Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marmé D, Lorusso PM. Siemann DW, et al. Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):416-20. Clin Cancer Res. 2005. PMID: 15701823 Review.

7

Inhibition of endothelial/smooth muscle cell contact loss by the investigational angiopoietin-2 antibody MEDI3617.

Molnar N, Siemann DW. Molnar N, et al. Among authors: siemann dw. Microvasc Res. 2012 May;83(3):290-7. doi: 10.1016/j.mvr.2012.02.008. Epub 2012 Feb 23. Microvasc Res. 2012. PMID: 22387475 Free PMC article.

8

Preclinical studies of the novel vascular disrupting agent MN-029.

Shi W, Siemann DW. Shi W, et al. Among authors: siemann dw. Anticancer Res. 2005 Nov-Dec;25(6B):3899-904. Anticancer Res. 2005. PMID: 16309177 Free article.

9

Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity.

Salmon HW, Siemann DW. Salmon HW, et al. Among authors: siemann dw. Clin Cancer Res. 2006 Jul 1;12(13):4090-4. doi: 10.1158/1078-0432.CCR-06-0163. Clin Cancer Res. 2006. PMID: 16818709

10

Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).

Siemann DW, Shi W. Siemann DW, et al. Anticancer Res. 2008 Jul-Aug;28(4B):2027-31. Anticancer Res. 2008. PMID: 18751370 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

243 results

Search Page

Filters